Kidney Cancer Trial, Recruiting NCT06598761 Sponsor: Peking University First Hospital Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT06598761
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had surgery to remove a kidney and ureter (called radical nephroureterectomy) and whose lab results confirmed cancer of the renal pelvis or ureter, at an advanced stage (classified as pT3-4 or pN+ under standard staging guidelines)
  • People whose kidneys are not filtering blood well enough (low eGFR below 60), or who have another health condition that means chemotherapy is not suitable for them
  • People aged between 18 and 80 years old
  • People who have had a CT scan of the abdomen and pelvis within 4 weeks before joining the trial
  • People who have not had any other cancer in the past 5 years, except for certain skin cancers (non-melanoma) or ductal carcinoma in situ of the breast
  • People who are willing to attend all required check-ups and follow-up visits for the study, and who are willing to sign a written consent form
  • People with an expected survival of more than 6 months and a general health score above 70 (on the Karnofsky scale, which measures ability to carry out daily activities) (confirm with trial site)
  • People whose blood test results meet minimum levels for white blood cells, a type of white blood cell called neutrophils, platelets, and haemoglobin (confirm with trial site for exact values)

Who may not be able to join:

  • People whose cancer had already spread to distant parts of the body at the time of surgery, or whose surgery did not remove all visible cancer
  • People who have previously had radiotherapy to the pelvis or abdomen, a history of inflammatory bowel disease, or prior chemotherapy treatment
  • People who are pregnant or breastfeeding, or women of childbearing age who are not using a reliable form of contraception
  • People who have had another cancer diagnosis in the past (except non-melanoma skin cancer, cervical cancer in situ, or cancers that were fully treated more than 5 years ago)
  • People who have lost more than 10% of their body weight in the past 6 months
  • People who have an active infection, or a pre-existing bleeding disorder (confirm with trial site)
  • People with significant heart or cardiovascular conditions, such as poorly controlled high blood pressure, unstable chest pain (angina), certain levels of heart failure, irregular heart rhythms causing symptoms, or significant circulation problems in the limbs
  • People whose psychological, family, or social circumstances mean they are not in a position to give informed consent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University First Hospital
Registry
ClinicalTrials.gov
Start date
1 January 2022
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

DFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov